Antihypertensive agents: a long way to safe drug prescribing in children

Area of Science:

• Pediatric pharmacology
• Cardiovascular medicine
• Clinical guidelines

Background:

• Updated clinical guidelines reveal significant gaps in pediatric hypertension understanding and management.
• Increased diagnosis of pediatric hypertension necessitates greater use of antihypertensive agents.
• Drug selection for pediatric hypertension is complicated by a lack of robust safety and efficacy trials.

Purpose of the Study:

• To review existing literature on the safety and efficacy of commonly prescribed antihypertensive agents in pediatric patients.
• To identify data gaps and areas requiring further research in pediatric hypertension pharmacotherapy.

Main Methods:

• Systematic literature review of antihypertensive agents used in pediatric populations.
• Analysis of available data on safety, efficacy, pharmacokinetics, and long-term risks.
• Focus on agents with increasing prescription rates in children.

Main Results:

• Angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB), and calcium channel blockers (CCB) have the most supporting data for pediatric use.
• Significant literature gaps exist for beta blockers and vasodilators.
• Long-term safety data for antihypertensive therapies in children remains largely unknown.

Conclusions:

• While ACE-I, ARB, and CCB show promise, further research is crucial for other drug classes.
• More pediatric-specific clinical trials are essential to establish safe and effective prescribing guidelines.
• Addressing literature gaps will improve the management of hypertension in children.